Here’s Why Vical (VICL) Shares Took a 30% Plunge Today

VICL logoNothing can kill a healthcare’s stock price like a failed clinical trial. Just take a look at the disaster that’s befallen Vical Incorporated (NASDAQ:VICL). The small cap vaccine maker’s share price has fallen 30% in recent market action to $1.14, on news that its therapeutic bivalent vaccine candidate for herpes simplex virus type 2 (HSV-2) did not meet its primary endpoint in the Phase 2 clinical study.

The Phase 2 study was conducted in 261 healthy HSV-2 seropositive adults, 18 to 50 years of age, with a self-reported history of 4 to 9 recurrences per year. Subjects were randomized 2:1 to receive either vaccine or placebo. The vaccine was generally safe and well tolerated, as assessed by an independent safety monitoring board; there were no grade 4 adverse events or serious adverse events reported related to vaccination.

“We took careful measures to recruit patients with self-reported history of 4 to 9 recurrences annually. Despite that, the annualized recurrence rate during the trial in the placebo group was far less than what was expected based on their self-reported history. As a result, there was significantly less power to show a vaccine effect in this trial,” said Vijay Samant, President and Chief Executive Officer. “We are extremely disappointed with the outcome and based upon these results, we will be terminating the HSV-2 program. We are indebted to our patients for their participation and our investigators for their steadfast support. The study protocol requires that patients be followed for 12 months after their last dose, and as a result we will continue to follow the active patients until July 2018.”

Mr. Samant continued, “In the meantime, we remain focused on our novel antifungal VL‑2397, which we licensed from Astellas and has the potential to be the first in a new class of antifungal drugs. Our Phase 2 trial is underway, comparing VL-2397 with standard first-line treatment for invasive aspergillosis in immunocompromised adults, which would be eligible for a Limited Use Indication assuming a successful outcome of the trial. In addition, we will continue the preclinical development of a novel treatment for chronic HBV infection based on our DNA and lipid-delivery technologies. The initial aim of our HBV program is to demonstrate proof of concept for inhibiting HBV infection in an in vivomodel.”

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts